ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 03 May 2017
Last Updated on 03 May 2017
A- A+
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours Guidance is outdated and has been withdrawn on 31 August 2022.
Denosumab for Bone Metastases (Withdrawn 31 Aug 2022)